Skip to main content
Top
Published in: European Journal of Medical Research 1/2019

Open Access 01-12-2019 | Colorectal Cancer | Research

Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway

Authors: Manuela Malsy, Diane Bitzinger, Bernhard Graf, Anika Bundscherer

Published in: European Journal of Medical Research | Issue 1/2019

Login to get access

Abstract

Background

Cancer, one of the leading causes of death worldwide, develops when the normal balance between mitosis and apoptosis is disrupted. The subsequently increased proliferation rate or decreased apoptosis rate of cells leads to uncontrolled cellular growth. Thus, the current aim of cancer research is to increase the apoptosis rate in tumor cells—while limiting the concurrent death of healthy cells—and to induce controlled apoptosis in abnormal cells. Staurosporine is a very potent inducer of apoptosis because it inhibits many different kinases. So far, many different kinase pathways of staurosporine-induced apoptosis have been discussed for various tumor entities.

Aims

To identify the effect of staurosporine in pancreatic and colorectal carcinoma cells and its apoptosis-inducing signaling pathway.

Methods

The apoptosis rate in pancreatic and colorectal carcinoma cells was analyzed by annexin V staining after staurosporine administration. Staurosporine stimulation and its effects on the expression of Bcl2, BAX, Bad, caspase-8, and caspase-9 were investigated with immunoblot.

Results

Staurosporine significantly increased apoptosis in pancreatic carcinoma cells. Western blot analysis showed activation of caspase-9 in PaTu 8988t and Panc-1 cells with 1 µM staurosporine. In addition, expression of Bcl2 and Bad was decreased in PaTu 8988t cells. In colorectal carcinoma cells SW 480, staurosporine stimulation did not induce apoptosis.

Conclusion

Modern therapeutic strategies for tumor diseases target the efficient modulation of specific signaling and transcription pathways. In this respect, the therapeutic potential of protein kinase inhibitors has been repeatedly discussed. Our study showed that staurosporine induces apoptosis in pancreatic carcinoma cells via the intrinsic signaling pathway. Thus, staurosporine is a suitable positive control for in vitro apoptosis tests for the pancreatic cancer cell lines PaTu 8988t and Panc-1. Further clinical studies should analyze the impact of this finding on cancer treatment.
Literature
1.
2.
go back to reference Oberholzer MJ. Pathologie verstehen, Molekulare Grundlagen der allgemeinen Pathologie. 2001; p. 55–64. Oberholzer MJ. Pathologie verstehen, Molekulare Grundlagen der allgemeinen Pathologie. 2001; p. 55–64.
3.
go back to reference Byrne H. The effect of time delay on the dynamics of avascular tumor growth. Math Biosci. 1997;144:83–117.CrossRef Byrne H. The effect of time delay on the dynamics of avascular tumor growth. Math Biosci. 1997;144:83–117.CrossRef
4.
go back to reference Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009;9:501–7.CrossRef Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer. 2009;9:501–7.CrossRef
5.
go back to reference Evan GI, Vousden KH. Proliferation cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.CrossRef Evan GI, Vousden KH. Proliferation cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.CrossRef
6.
go back to reference Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845.PubMedPubMedCentral Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014;2014:150845.PubMedPubMedCentral
7.
8.
go back to reference De Felici M, Piacebtini M. Programmed cell death in development and tumors. Int J Dev Biol. 2015;59:1–3.CrossRef De Felici M, Piacebtini M. Programmed cell death in development and tumors. Int J Dev Biol. 2015;59:1–3.CrossRef
9.
go back to reference Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45:487–98.CrossRef Ouyang L, Shi Z, Zhao S, Wang FT, Zhou TT, Liu B, Bao JK. Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis. Cell Prolif. 2012;45:487–98.CrossRef
10.
go back to reference Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543–67.CrossRef Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543–67.CrossRef
11.
12.
go back to reference Barnhart BC, Lee JC, Alappat EC, Peter ME. The death effector domain protein family. Oncogene. 2003;22:8634–44.CrossRef Barnhart BC, Lee JC, Alappat EC, Peter ME. The death effector domain protein family. Oncogene. 2003;22:8634–44.CrossRef
13.
go back to reference Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett. 2009;281:128–33.CrossRef Fulda S. Caspase-8 in cancer biology and therapy. Cancer Lett. 2009;281:128–33.CrossRef
14.
go back to reference Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19:325–31.CrossRef Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008;19:325–31.CrossRef
15.
go back to reference Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol. 2010;2010:1–6. Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol. 2010;2010:1–6.
16.
go back to reference Schafer ZT, Kornbluth S. The apoptosome: physiological, developmental and pathological modes of regulation. Dev Cell. 2006;10:549–61.CrossRef Schafer ZT, Kornbluth S. The apoptosome: physiological, developmental and pathological modes of regulation. Dev Cell. 2006;10:549–61.CrossRef
17.
go back to reference Zhang XD, Gillespie SK, Hersey P. Staurosporine induced apoptosis of melanoma by both caspase-dependent and independent apoptotic pathways. Mol Cancer Ther. 2004;3:187–97.PubMed Zhang XD, Gillespie SK, Hersey P. Staurosporine induced apoptosis of melanoma by both caspase-dependent and independent apoptotic pathways. Mol Cancer Ther. 2004;3:187–97.PubMed
18.
go back to reference Stepczynska A, Lauber K, Engels IH, Janssen O, Kabelitz D, Wesselborg S, Schulze- Osthoff K. Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene. 2001;20:1193–202.CrossRef Stepczynska A, Lauber K, Engels IH, Janssen O, Kabelitz D, Wesselborg S, Schulze- Osthoff K. Staurosporine and conventional anticancer drugs induce overlapping, yet distinct pathways of apoptosis and caspase activation. Oncogene. 2001;20:1193–202.CrossRef
19.
go back to reference Yadav SS, Prasad CB, Prasad SB, Pandey LK, Singh S, Pradhan S, Narayan G. Anti- tumor activity of staurosporine in the tumor microenvironment of cervical cancer: an in vitro study. Life Sci. 2015;133:21–8.CrossRef Yadav SS, Prasad CB, Prasad SB, Pandey LK, Singh S, Pradhan S, Narayan G. Anti- tumor activity of staurosporine in the tumor microenvironment of cervical cancer: an in vitro study. Life Sci. 2015;133:21–8.CrossRef
20.
go back to reference Zhao L, Lu G, Zhao Q, Zhang M, Chen M, Zhang J, Dai K. Staurosporine induces platelet apoptosis through p38 mitogen-activated protein kinase signaling pathway. Clin Lab. 2015;61:717–26.PubMed Zhao L, Lu G, Zhao Q, Zhang M, Chen M, Zhang J, Dai K. Staurosporine induces platelet apoptosis through p38 mitogen-activated protein kinase signaling pathway. Clin Lab. 2015;61:717–26.PubMed
21.
go back to reference Nardo T, Micalizzi G, Vicinanza R, De Iuliis F, Taglieri L, Scarpa S. Adhesion to type V collagen enhances staurosporine-induced apoptosis of adrenocortical cancer cells. Tumour Biol. 2014;35:9949–55.CrossRef Nardo T, Micalizzi G, Vicinanza R, De Iuliis F, Taglieri L, Scarpa S. Adhesion to type V collagen enhances staurosporine-induced apoptosis of adrenocortical cancer cells. Tumour Biol. 2014;35:9949–55.CrossRef
22.
go back to reference Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapie. Oncogene. 2006;25:4798–811.CrossRef Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapie. Oncogene. 2006;25:4798–811.CrossRef
23.
go back to reference Hamacher R, Schmid R, Saur D, Schneider G. Apoptotic pathways in pancreatic ducal adenocarcinoma. Mol Cancer. 2008;7:1–10.CrossRef Hamacher R, Schmid R, Saur D, Schneider G. Apoptotic pathways in pancreatic ducal adenocarcinoma. Mol Cancer. 2008;7:1–10.CrossRef
24.
go back to reference Besbes S, Mirshahi M, Pocard M, Billard C. New dimension in therapeutic targeting of BCL2 family proteins. Oncotarget. 2015;6:12862–71.CrossRef Besbes S, Mirshahi M, Pocard M, Billard C. New dimension in therapeutic targeting of BCL2 family proteins. Oncotarget. 2015;6:12862–71.CrossRef
25.
go back to reference Bundscherer A, Malsy M, Bitzinger D, Graf BM. Interaction of anesthetics with tumor cells. Anaesthesist. 2014;63:313–25.CrossRef Bundscherer A, Malsy M, Bitzinger D, Graf BM. Interaction of anesthetics with tumor cells. Anaesthesist. 2014;63:313–25.CrossRef
26.
go back to reference Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct activation of Bax protein for cancer therapy. Med Res Rev. 2016;36:313–41.CrossRef Liu Z, Ding Y, Ye N, Wild C, Chen H, Zhou J. Direct activation of Bax protein for cancer therapy. Med Res Rev. 2016;36:313–41.CrossRef
27.
go back to reference Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–32.CrossRef Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 2009;15:1126–32.CrossRef
29.
go back to reference Zeidner JF, Karp JE. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res. 2015;39:1312–8.CrossRef Zeidner JF, Karp JE. Clinical activity of alvocidib (flavopiridol) in acute myeloid leukemia. Leuk Res. 2015;39:1312–8.CrossRef
30.
go back to reference Ou SH, Soo RA. Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? Drug Des Devel Ther. 2015;9:5641–53.CrossRef Ou SH, Soo RA. Dacomitinib in lung cancer: a “lost generation” EGFR tyrosine-kinase inhibitor from a bygone era? Drug Des Devel Ther. 2015;9:5641–53.CrossRef
31.
go back to reference Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, Oh SM, Kim HM, Chae SW, Kim HR. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000;42:373–81.CrossRef Chae HJ, Kang JS, Byun JO, Han KS, Kim DU, Oh SM, Kim HM, Chae SW, Kim HR. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol Res. 2000;42:373–81.CrossRef
32.
go back to reference Xue LY, Chiu SM, Oleinick NL. Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions. Exp Cell Res. 2003;283:135–45.CrossRef Xue LY, Chiu SM, Oleinick NL. Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions. Exp Cell Res. 2003;283:135–45.CrossRef
33.
go back to reference Wang Y, Yang H, Liu H, Huang J, Song X. Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer. 2009;9:174.CrossRef Wang Y, Yang H, Liu H, Huang J, Song X. Effect of staurosporine on the mobility and invasiveness of lung adenocarcinoma A549 cells: an in vitro study. BMC Cancer. 2009;9:174.CrossRef
34.
go back to reference Talaiezadeh A, Jalali F, Galehdari H, Khodadadi A. Time depended Bcl-2 inhibition might be useful for a targeted drug therapy. Cancer Cell Int. 2015;15:105.CrossRef Talaiezadeh A, Jalali F, Galehdari H, Khodadadi A. Time depended Bcl-2 inhibition might be useful for a targeted drug therapy. Cancer Cell Int. 2015;15:105.CrossRef
35.
go back to reference Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071–80.CrossRef Delbridge AR, Strasser A. The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ. 2015;22:1071–80.CrossRef
36.
go back to reference Vela L, Marzo I. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr Opin Pharmacol. 2015;23:74–81.CrossRef Vela L, Marzo I. Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside. Curr Opin Pharmacol. 2015;23:74–81.CrossRef
37.
go back to reference Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88:386–401.PubMed Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996;88:386–401.PubMed
38.
go back to reference Yuste VJ, Sanchez-Lopez I, Sole C, Encinas M, Bayascas JR, Boix J, Comella JX. The prevention of the staurosporine-induced apoptosis by Bcl-X(L), but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells. J Neurochem. 2002;80:126–39.CrossRef Yuste VJ, Sanchez-Lopez I, Sole C, Encinas M, Bayascas JR, Boix J, Comella JX. The prevention of the staurosporine-induced apoptosis by Bcl-X(L), but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells. J Neurochem. 2002;80:126–39.CrossRef
39.
go back to reference Adams JM, Huang DC, Strasser A, Willis S, Chen L, Wei A, van Delft M, Fletcher JI, Puthalakath H, Kuroda J, Michalak EM, Kelly PN, Bouillet P, Villunger A, O’Reilly L, Bath ML, Smith DP, Egle A, Harris AW, Hinds M, Colman P, Cory S. Subversion of the Bcl-2 life/death switch in cancer development and therapy. Cold Spring Harb Symp Quant Biol. 2005;70:469–77.CrossRef Adams JM, Huang DC, Strasser A, Willis S, Chen L, Wei A, van Delft M, Fletcher JI, Puthalakath H, Kuroda J, Michalak EM, Kelly PN, Bouillet P, Villunger A, O’Reilly L, Bath ML, Smith DP, Egle A, Harris AW, Hinds M, Colman P, Cory S. Subversion of the Bcl-2 life/death switch in cancer development and therapy. Cold Spring Harb Symp Quant Biol. 2005;70:469–77.CrossRef
40.
go back to reference Bidart M, Berger F, Pelletier L. Anti-angiogenetic therapies: from theory to practice. Ann Biol Clin. 2013;71:527–35. Bidart M, Berger F, Pelletier L. Anti-angiogenetic therapies: from theory to practice. Ann Biol Clin. 2013;71:527–35.
41.
go back to reference Burger J, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalling. Blood. 2013;121:1501–9.CrossRef Burger J, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalling. Blood. 2013;121:1501–9.CrossRef
42.
go back to reference Modest D, Hiddemann W, Heinemann V. Chemotherapy of metastatic colorectal cancer. Internist. 2014;55:37–42.CrossRef Modest D, Hiddemann W, Heinemann V. Chemotherapy of metastatic colorectal cancer. Internist. 2014;55:37–42.CrossRef
43.
go back to reference Chahrour O, Cairns D, Omran Z. Small molecule kinase inhibitors as anti-cancer therapeutics. Mini Rev Med Chem. 2012;12:399–411.CrossRef Chahrour O, Cairns D, Omran Z. Small molecule kinase inhibitors as anti-cancer therapeutics. Mini Rev Med Chem. 2012;12:399–411.CrossRef
44.
go back to reference Novak K. Conference report-protein kinase inhibitors in cancer treatment: mixing and matching? Highlights of the keystone symposium on protein kinases and cancer. MedGenMed. 2004;6:25.PubMedPubMedCentral Novak K. Conference report-protein kinase inhibitors in cancer treatment: mixing and matching? Highlights of the keystone symposium on protein kinases and cancer. MedGenMed. 2004;6:25.PubMedPubMedCentral
45.
go back to reference Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296–313.CrossRef Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov. 2003;2:296–313.CrossRef
Metadata
Title
Staurosporine induces apoptosis in pancreatic carcinoma cells PaTu 8988t and Panc-1 via the intrinsic signaling pathway
Authors
Manuela Malsy
Diane Bitzinger
Bernhard Graf
Anika Bundscherer
Publication date
01-12-2019
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2019
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-019-0365-x

Other articles of this Issue 1/2019

European Journal of Medical Research 1/2019 Go to the issue